119 related articles for article (PubMed ID: 15809899)
21. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
22. Plasma levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI-APOE cluster.
Waterworth DM; Hubacek JA; Pitha J; Kovar J; Poledne R; Humphries SE; Talmud PJ
J Lipid Res; 2000 Jul; 41(7):1103-9. PubMed ID: 10884292
[TBL] [Abstract][Full Text] [Related]
23. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
24. ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy.
Almeida S; Fiegenbaum M; de Andrade FM; Osório-Wender MC; Hutz MH
Maturitas; 2006 May; 54(2):119-26. PubMed ID: 16242874
[TBL] [Abstract][Full Text] [Related]
25. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue.
den Boer MA; Berbée JF; Reiss P; van der Valk M; Voshol PJ; Kuipers F; Havekes LM; Rensen PC; Romijn JA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):124-9. PubMed ID: 16269669
[TBL] [Abstract][Full Text] [Related]
26. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels.
Laws SM; Perneczky R; Wagenpfeil S; Müller U; Förstl H; Martins RN; Kurz A; Riemenschneider M
Hum Mutat; 2005 Jul; 26(1):29-35. PubMed ID: 15895461
[TBL] [Abstract][Full Text] [Related]
27. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients.
Vaisi-Raygani A; Rahimi Z; Nomani H; Tavilani H; Pourmotabbed T
Clin Biochem; 2007 Oct; 40(15):1150-6. PubMed ID: 17689519
[TBL] [Abstract][Full Text] [Related]
28. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.
Fontaine-Bisson B; Wolever TM; Chiasson JL; Rabasa-Lhoret R; Maheux P; Josse RG; Leiter LA; Rodger NW; Ryan EA; El-Sohemy A
Metabolism; 2007 May; 56(5):649-55. PubMed ID: 17445540
[TBL] [Abstract][Full Text] [Related]
30. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
Arikan H; Koc M; Sari H; Tuglular S; Ozener C; Akoglu E
Ren Fail; 2007; 29(6):713-9. PubMed ID: 17763167
[TBL] [Abstract][Full Text] [Related]
31. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
[TBL] [Abstract][Full Text] [Related]
32. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins.
Hegele RA; Connelly PW; Hanley AJ; Sun F; Harris SB; Zinman B
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2753-8. PubMed ID: 9409252
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
[TBL] [Abstract][Full Text] [Related]
34. [The relationship between apolipoprotein E genotype and hypertriglyceridemia-associated recurrent acute pancreatitis].
WEN T; LIU L; NIE S
Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(20):1579-82. PubMed ID: 19094657
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein CIII and highly active antiretroviral therapy (HAART)-induced hypertriglyceridemia.
Badiou S; Dupuy AM; Baillat V; Fabre J; Tur MD; Cristol JP; Reynes J
Clin Lab; 2003; 49(1-2):11-3. PubMed ID: 12593470
[No Abstract] [Full Text] [Related]
36. Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men.
Waterworth DM; Talmud PJ; Bujac SR; Fisher RM; Miller GJ; Humphries SE
Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2663-9. PubMed ID: 11116069
[TBL] [Abstract][Full Text] [Related]
37. Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein.
Chasman DI; Kozlowski P; Zee RY; Kwiatkowski DJ; Ridker PM
Genes Immun; 2006 Apr; 7(3):211-9. PubMed ID: 16511556
[TBL] [Abstract][Full Text] [Related]
38. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
39. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
